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227 Abstract
28 Purpose: We conducted a systematic review and meta-analysis to evaluate the efficacy of 
29 different treatment for Demodex blepharitis. Parameters studied were mites count, 
30 improvement of symptoms and mites’ eradication, stratified on type of treatments and mode of 
31 delivery of treatments (local or systemic).
32 Method: The PubMed, Cochrane Library, Embase, ClinicalTrials.gov, Google scholar and 
33 Science Direct databases were searched for studies reporting an efficacy of treatments for 
34 Demodex blepharitis.
35 Results: We included 19 studies (14 observational and 5 randomized clinical trials), for a total 
36 of 934 patients, 1741 eyes, and 13 different treatments. For mites count, eradication rate, and 
37 symptoms improvement, meta-analysis included fifteen, fourteen and thirteen studies, 
38 respectively. The overall effect sizes for efficiency of all treatments, globally, were 1.68 (95CI 
39 1.25 to 2.12), 0.45 (0.26 to 0.64), and 0.76 (0.59 to 0.90), respectively. Except usual lid hygiene 
40 for mites count, Children's Hospital of Eastern Ontario ointment (CHEO) for both eradication 
41 rate and symptoms, and CHEO, 2% metronidazole ointment, and systemic metronidazole for 
42 symptoms, all treatments were efficient. Stratified meta-analysis did not show significant 
43 differences between local and systemic treatments (1.22, 0.83 to 1.60 vs 2.24, 1.30 to 3.18 for 
44 mites count; 0.37, 0.21 to 0.54 vs 0.56, 0.06 to 0.99 for eradication rate; and 0.77, 0.58 to 0.92 
45 vs 0.67, 0.25 to 0.98 for symptoms improvement).
46 Conclusion: We reported the efficiency of the different treatments of Demodex blepharitis. 
47 Because of less systemic side effects, local treatments seem promising molecules in the 
48 treatment of Demodex blepharitis.
49
50 Keywords: Demodex – Blepharitis – Infection – Immunology – Inflammation – Tea tree oil – 
51 Ivermectin – Pilocarpine – Metronidazole
352 Introduction
53 Blepharitis is a common eye inflammation affecting eyelash, eyelid and ocular surface with 
54 sometimes corneal resounding. Among many causes, Demodex mites are found since the 19th 
55 century with princep observation by Henle and Simon [1,2]. There are two host-specific 
56 obligate mites’ species found in human being’s hair follicles, sebaceous glands (Zeiss ‘glands) 
57 and eyelid glands (Meibum’s glands) causing anterior and posterior blepharitis: Demodex 
58 folicularum and Demodex brevis. Typically, Demodex folicularum found in clusters around the 
59 eyelash and eyelid skin whereas Demodex brevis resided alone in the deep of sebaceous and 
60 Meibomian glands [3–5]. Mites’ presence may cause inflammatory process in some eyelid 
61 tissues, however the pathogenesis’ role of Demodex in inflammatory process of blepharitis is 
62 discussed. Demodex would be the vector for number of bacterial and mycotic pathogens, 
63 resulting in an immunological response at the eyelid margins, with redness, itching and burning 
64 sensations [6–8]. Diagnosis of Demodex blepharitis is classically obtained by parasitologist 
65 with skin or follicles biopsies [1–6,8,9] or more recently by confocal microscopy [10,11]. 
66 Cylindrical dandruff at the base of eyelash is considered as pathognomonic of Demodex 
67 infestation [5,12,13].
68 This physiological lack of knowledge and saprophyte presence of Demodex in healthy eyes 
69 have an impact on therapeutics with very few studies in international scientific literature. 
70 During long years, usual lid hygiene has been used to treat this kind of resistant blepharitis, 
71 sometimes with sulphuric ointment [1], yellow mercuric ointment [1,4,9,14], pilocarpine gel 
72 [15,16] or locals’ antibiotics [17] without proof of efficacy. Anthelminthics, with systemic side 
73 effects, have been used empirically these last years [18–21]. New local therapy based on tea 
74 tree oil (TTO) and terpinen-4-ol (T4O) have been tested recently [18,21–32], opening a new 
75 therapeutic field. To our knowledge, there are no synthesis of literature comparing Demodex 
76 treatments. To allow a future consensus or new treatment elaboration is of major interest.
477 Therefore, we aimed to compute a systematic review and meta-analysis to compare all efficacy 
78 of Demodex blepharitis treatments. More specifically, we aimed assess the comparative 
79 efficiency of local and systemic treatments and to evaluate influencing parameters in 
80 therapeutic efficacy.
81
82 Methods
83 Literature search
84 We have searched all articles in PubMed, The Cochrane Library, Central, Embase, 
85 ClinicalTrial.gov, Google Scholar and ScienceDirect databases from February 2018 to August 
86 2018 with following keywords: (blepharitis OR blepharitides) AND (drug* OR 
87 pharmacotherapy OR therap* OR treat* OR administration OR patient* OR outcome* OR 
88 efficacy OR effective* OR clinical OR management OR compliance OR adherence). We 
89 limited our search to articles written in English, French, or Spanish. No minimal sample size 
90 was applied. To be included, articles needed to evaluate a therapy concerning Demodex 
91 blepharitis proved by parasitological examination or confocal microscopy or cylindrical 
92 dandruff. We imposed no limitation of regional origin or control group nature. In addition, 
93 references list of all publications was manually searched to identify any other ones not found 
94 with electronic search. The search strategy is presented in Figure 1. One author conducted all 
95 literature searches (Valentin Navel) and collated the abstracts. Two authors (Valentin Navel 
96 and Cédric Benoist d’Azy) separately reviewed the abstracts and based on the selection criteria, 
97 decided the suitability of the articles for inclusion. A third author (Frédéric Dutheil) was asked 
98 to review the articles where consensus on suitability was debated. Finally, all authors reviewed 
99 eligible articles.
100 Quality of assessment
5101 Although not created for that, the “Strengthening the Reporting of Observational studies in 
102 Epidemiology” (STROBE) criteria may be inappropriately used as an assessment tool to judge 
103 study quality, as well as the CONSORT guidelines for randomized clinical trials. STROBE and 
104 CONSORT are checklists of 22 and 30 items, respectively. We attributed one point per items, 
105 then converted into percentage to give a quality score for each included study [33–36]. 
106 We also used the SIGN criteria to also judge observational studies and randomized clinical 
107 trials, with the dedicated evaluation grids. SIGN Cohort Studies and SIGN Controlled Trials 
108 statements are a checklist of 18 and 14 items, respectively. We gave a general quality score for 
109 each include study based on the main causes of bias evaluated in section 1 of both checklists 
110 through 4 possibilities of answers (yes, no, can’t say or not applicable) [37].
111
112 Statistical considerations
113 Statistical analyses were performed using Stata (v12, StataCorp, US) [38–44]. Parameters were 
114 reported as mean ± standard-deviation (SD) or number (%) for continuous or categorical 
115 variables. Treatment efficacy was assessed using Hedges bias corrected effect size (ES) of 
116 parasite count evolution (before-after treatment) as primary outcome. Parasite eradication rate 
117 and symptoms improvement rate were considered as secondary outcome. ES and 95% 
118 confidence interval (CI) were presented on forest plots, as a unitless measure of the effects of 
119 treatments for Demodex blepharitis on mites count, eradication rate, and symptoms 
120 improvement. An ES centered at zero means the absence of efficacy, 0.2 a small effect, 0.5 a 
121 moderate effect, and 0.8 a large effect [45]. Funnel plots assessed the publication bias. I-squared 
122 (I2) quantified heterogeneity between studies, graded as low (<25%), moderate (25-50%) or 
123 high (>50%). All statistical tests were two-sided; significance was set for p<0.05. When sample 
124 size was sufficient, meta-regressions (expressed as regression coefficient and 95% CI) were 
6125 proposed to study relationships between parameters variation and clinically relevant parameters 
126 such as age, sex ratio and eyelash sampling method.
127
128 Results
129 With the keywords described, an initial search produced 2796 articles (Fig 1). After removal of 
130 the duplicates and applying selection criteria, we included 19 articles [14–16,18,18–32]. 
131
132 More details on study characteristics, quality of articles (Figures 2 and 3), method of Demodex 
133 identification, type of treatments, protocol for each treatment, inclusion and exclusion criteria 
134 of each included study, population, aims and outcomes of included studies are described in 
135 Appendix 1.
136
137 Meta-analyses and meta-regressions
138 Mites count: Fifteen studies were included [14,16,19–25,27–32] with an overall ES of 1.68 
139 (95CI 1.25 to 2.12) for all treatments. Except usual lid hygiene, all treatments decreased mites 
140 count (Fig 4 and Fig 5, and Appendix 2). Stratified meta-analysis did not show significant 
141 differences between local (1.22, 0.83 to 1.60) and systemic (2.24, 1.30 to 3.18) treatments (Fig 
142 6 and 7), or between eyelash sampling with (1.31, 0.80 to 1.81) or without (1.49, 1.02 to 1.96) 
143 cylindrical dandruff (Fig 6, and Appendix 5). There were also no significant influences of age 
144 and gender (Fig 6). Meta-regressions comparing treatments efficacy were not feasible due to 
145 limited number of data (most treatments were only reported in one study), despite stratified 
146 meta-analysis on each treatment demonstrated ES greater than 2.5 for oral metronidazole + oral 
147 ivermectin (3.66, 95CI 2.84 to 4.48), and 5%TTO (2.66, 2.17 to 3.15); greater than 1 for 
148 ivermectin alone (1.80, 1.10 to 2.50), 50%TTO (1.74, 0.81 to 2.67), pilocarpine gel (1.72, 0.71 
149 to 2.73), and T4O (1.36, 0.60 to 2.11); and greater than 0.8 for Cilclar 1.9% + oxide mercuric 
7150 ointment + ether application (0.81, 0.26 to 1.34), CHEO (0.53, 0.12 to 0.94) and OLSP (0.95, 
151 0.53 to 1.37) (Fig 4 and 5, and Appendix 2).
152 Eradication rate of mites: Fourteen studies were included [14,15,18,20–24,27,29–32,46] with 
153 an overall ES of 0.45 (0.26 to 0.64) for all treatments. Except CHEO, 2% metronidazole 
154 ointment, and systemic metronidazole, all treatments improved eradication rate (Fig 4 and 5, 
155 and Appendix 3). Stratified meta-analysis did not show significant differences between local 
156 (0.37, 0.21 to 0.54) and systemic (0.56, 0.06 to 0.99) treatments (Fig 6 and 7), or between 
157 eyelash sampling with (0.30, 0.12 to 0.51) or without (0.46, 0.25 to 0.68) cylindrical dandruff 
158 (Fig 6, and Appendix 5). As for mites count, there were also no significant influences of age 
159 and gender (Fig 6), and meta-regressions comparing treatments efficacy were also not feasible 
160 due to limited number of data (one study per treatment, mainly). However, stratified meta-
161 analysis on each treatment demonstrated ES greater than 0.8 for systemic metronidazole + 
162 ivermectin (1.00, 0.80 to 1.00), and pilocarpine gel (0.92, 0.81 to 0.97); greater than 0.5 for 
163 Cilclar 1.9% + oxide mercuric ointment + ether application (0.57, 0.33 to 0.59), 50%TTO (0.54, 
164 0.25 to 0.82), and ivermectin (0.54, 0.01 to 1.00); and greater than 0.2 for Ocusoft lid scrub 
165 (0.46, 0.28 to 0.65), 5%TTO (0.43, 0.04 to 0.87), T4O (0.41, 0.23 to 0.61), and usual lid hygiene 
166 (0.22, 0.02 to 0.53) (Fig 4 and 5, and Appendix 3).
167 Symptoms improvement: Thirteen studies were included [14–16,18,19,21–24,26,28,31,32,46] 
168 with an overall ES of 0.76 (0.59 to 0.90) for all treatments. Except CHEO, all treatments 
169 improved symptoms (Fig 4 and 5, and Appendix 4). Stratified meta-analysis did not show 
170 significant differences between local (0.77, 0.58 to 0.92) and systemic (0.67, 0.25 to 0.98) 
171 treatments (Fig 6 and 7), or between eyelash sampling with (0.81, 0.37 to 1.00) or without (0.73, 
172 0.55 to 0.89) cylindrical dandruff (Fig 6, and Appendix 5). As for mites count and eradication 
173 rate, there were also no significant influences of age and gender (Fig 6), and meta-regressions 
174 comparing treatments efficacy were also not feasible due to limited number of data (one study 
8175 per treatment, mainly). CHEO were less efficient than usual lid hygiene with a coefficient of 
176 -1.02 (-1.33 to -0.71) (Fig 6). However, stratified meta-analysis on each treatment demonstrated 
177 ES greater than 0.8 for T4O (1.00, 0.85 to 1.00), Ocusoft lid scrub (1.00, 0.86 to 1.00), 50% 
178 TTO (0.97, 0.86 to 1.00) and 5% TTO (0.81, 0.60 to 0.96); greater than 0.5 for Cilclar 1.9% + 
179 oxide mercuric ointment + ether application (0.79, 0.52 to 0.92), systemic ivermectin (0.78, 
180 0.31 to 1.00), 4% pilocarpine gel (0.74, 0.60 to 0.84) and usual lid hygiene (0.54, 0.42 to 0.65); 
181 and greater than 0.2 for Naviblef (0.41, 0.26 to 0.57), 2% metronidazole ointment (0.20, 0.04 
182 to 0.62) and systemic metronidazole (0.20, 0.04 to 0.62) (Fig 4 and 5, and Appendix 4).
183
184 Discussion
185 Our study is the first systematic evaluation of treatments for Demodex blepharitis. 
186 Physiopathology of this commensal parasite were a hindrance to the development of various 
187 therapies. We reported the efficiency of the different treatments of Demodex blepharitis. More 
188 interestingly, stratified meta-analysis did not show significant differences between local and 
189 systemic treatments. Because of less side effects, local treatments seem promising to manage 
190 Demodex blepharitis. We did not demonstrate influence of sociodemographic in the efficacy of 
191 treatments.
192
193 Rational of study
194 Despite Demodex was first identified 150 years ago, it only attracted wider interest recently, 
195 over the last 10 years [1]. In fact, the relative current ignorance of physiopathology is a 
196 drawback in therapeutics’ evaluations. Initially, Demodex was considered as a saprophyte 
197 parasite normally colonising the eyelashes. Current consensus proposed to consider as 
198 physiological a number of mites <5 mites/cm2 for skin lesions or <3 mites at the root of each 
199 eyelash [4,20,47]. However, mites outbreaks may play a role in the pathophysiology of the 
9200 infection, causing a local inflammatory reaction and a repercussion on the ocular surface 
201 [1,5,8,9,13,48–50]. Therefore, several therapeutics were used such as antiparasitic, antiseptics, 
202 or anti-inflammatory drugs. Our meta-analysis was needed because most treatments were used 
203 without sound proof of efficiency and without randomized controlled trials comparing 
204 efficiency of treatments. We chose Demodex count as primary judgement criteria because the 
205 presence of some mites may be considered as normal and outbreaks pathological. Eradication 
206 rate was chosen as a secondary judgement criteria to evaluate the in vivo killing effect in parallel 
207 of mites count decrease.
208
209 Interest molecules
210 Initially, usual lid hygiene has been used to treat resistant blepharitis with sulphuric ointment 
211 [1], yellow mercuric ointment [1,4,9,14] or pilocarpine gel [15,16]. Sulphuric ointment or 
212 yellow mercury treatments were poorly supported and are now obsolete (last publications are 
213 more than twenty years old) [2,5,13,51,52] whereas pilocarpine, a well-known molecule in 
214 glaucoma, showed interesting results with gel form [15,16]. Its antiparasitic effect may be based 
215 on parasympathomimetic action resulting in paralysis of mites’ respiration and mobility 
216 [15,16]. Over the last three decades, anthelminthics, such as ivermectin or metronidazole, were 
217 used empirically to treat Demodex blepharitis, as an off-label drug prescription outside 
218 marketing authorisation [18–21]. Ivermectin is an effective orally administered antiparasitic 
219 drug, known since several years. Whereas the acaricidal effect of metronidazole on the 
220 Demodex mite is unknown [20,53,54], the parasitic killing effect of ivermectin is well known, 
221 through a selective activity against glutamate-gated chloride ion channels from the peripheral 
222 nervous system of invertebrates. These last years, news locals’ therapies based on TTO and 
223 T4O have been tested [18,21–32], opening a new therapeutic field. TTO is a natural substance 
224 extracted from the leaves of the Melaleuca alternifolia, a plant of the Myrtaceae family. This 
10
225 product was known for a long time by Australian indigenous concerning antiseptic properties 
226 [55,56]. Some studies concerning TTO proved its antifungal, antibacterial, antiviral and 
227 antiparasitological effects [57–61]. T4O is the most active ingredient of TTO with 
228 concentration from 30 to 48% [56]. The results of TTO, T4O and pilocarpine uses corroborated 
229 the results of in vitro killing effect [27]. To our knowledge, in most countries, no treatment 
230 based on TTO or T4O are available to clinicians with marketing authorisation to treat Demodex 
231 blepharitis. It would be interesting to evaluate these news locals’ treatments in clinical trials to 
232 prove their efficacy, and to consider these molecules in therapeutic association.
233
234 Proposal of recommendations for the treatment of Demodex blepharitis
235 In our meta-analysis, all Demodex blepharitis included from individual studies were resistant 
236 to the first-line treatment such as usual lid hygiene and local antibiotics [14–16,18–32,46]. 
237 Thus, negative results of usual lid hygiene were expected. However, its mechanical effects have 
238 been proved and should at an early stage [17,62–64]. More interestingly, we demonstrated that 
239 local and systemic treatments had comparable efficiency (1.22, 0.83 to 1.60 vs 2.24, 1.30 to 
240 3.18 for mites count; 0.37, 0.21 to 0.54 vs 0.56, 0.06 to 0.99 for eradication rate; and 0.77, 0.58 
241 to 0.92 vs 0.67, 0.25 to 0.98 for symptoms improvement). As mentioned upper, Demodex mites 
242 are present in healthy eyelids so it could be unnecessary to employ toxic or very effective 
243 systemic treatment. In included studies, clinical side effects or hepatic toxicity were not 
244 observed with systemic ivermectin or metronidazole [18,19,21]. However, hypersensitivity 
245 reaction is more common with systemic treatments compared with local treatments. Serious 
246 reactions were observed using ivermectin or metronidazole in other parasitic infections such as 
247 Mazzotti reaction (tachycardia, hypotension, arthralgias, oedema, and abdominal pain), Steven-
248 Johnson and Lyell disease, fatal encephalopathy, increased INR (International Normalized 
249 Ratio) with hemorrhage, decrease in leukocyte count and anemia, hepatitis, elevation of liver 
11
250 enzymes, and elevation of bilirubin. Ivermectin should not be used during pregnancy since 
251 safety in pregnancy has not been established [20,21,53,54]. In blepharitis Demodex, the sides 
252 effects with local uses of TTO, T4O or pilocarpine were rare and benign, such as eyes 
253 irritations, redness eyelid, cutaneous eczema, itching or burning sensations, but never systemic 
254 reactions [14,18,22–32,46]. Therefore, considering that cylindrical dandruffs at the base of the 
255 eyelashes are pathognomonic of Demodex blepharitis [5,13,27], and considering our results, 
256 we propose to treat blepharitis with cylindrical dandruffs with antiparasitic local first-line 
257 treatment i.e. the association of TTO, T4O or pilocarpine gel with usual lid hygiene once or
258 twice daily during 1 to 3 months. In second-line or in severe cases, systemic treatment such as 
259 ivermectin or metronidazole could be added, which may also decrease recurrence – although 
260 not proved –, without severe side effects reported with systemic low dose in the treatment of 
261 Demodex blepharitis. Severe cases refer to severe ocular repercussions such as keratitis, corneal 
262 ulcer, severe itching with skins lesions, trichiasis, ectropion or entropion with corneal lesions. 
263 Combination of both systemic and local treatment may also be interesting in some putative 
264 facial extensive Demodex outbreaks, such as rosacea [65–67]. 
265
266 Parameters influencing therapeutics
267 In epidemiological studies, the influence of socio-demographic parameters on mites count was 
268 controversial. It was described a higher prevalence of infestation in people with oily or mixed 
269 skin than with dry or neutral skin [68–71], in humid-tropical climate [72], in 
270 immunocompromised patients [73–77], or in childhood malnutrition [78]. Majority of studies 
271 concluded on an increase of mites count with age [1,68,79,80], which may be explained by the 
272 decreasing activity of the glands of Zeiss and the Meibomian glands with age [1,50,81]. 
273 However, in paediatric and teenage population, Demodex mites could played a pathological 
274 role in recurrent chalazia, itching and redness eyelid [28,30]. Differences between socio-
12
275 demographic results could be explained by variability of inclusion criteria. According to meta-
276 regression results, we did not find significant influences of age and gender on mites count. Most 
277 of included studies were epidemiological and recruited patients during conventional 
278 examination for refractive or pre-surgical consultations. Many patients in these consultations 
279 may have not complained of any symptoms whereas all patients in our study were recruited 
280 because of chronic blepharitis (thus with a high probability of complaints). 
281
282 Limitations
283 Our study had some limitations. Data collections and inclusion/exclusion criteria were not 
284 identical within each studies, which may have affected our results, as well as heterogeneity due 
285 to different study designs – retrospective [18,22,24,30] or prospective studies, randomized 
286 [15,20,25,29,31] or not [14,16,19,21,23,26–28,32,46]. Nevertheless, we combined a large 
287 number of patients and procedures to permit a large overview, with sensitivity analyses (data 
288 not shown) demonstrating similar results whatever study designs. Studies included small 
289 samples and were exclusively monocenter, precluding generalizability. Though, all continents 
290 and all ethnicities were included. Moreover, we cover nearly 30 years of treatments of Demodex 
291 blepharitis, with a wide range of therapeutics. However, the apparition of new treatments 
292 precluded efficacy analyses of same treatments over time. All studies used conventional 
293 parasitological examination to prove Demodex infestation. Despite different number of 
294 eyelashes sampled between included studies, and thus difference between studies concerning 
295 mite’s count before treatment, it did not influence our results because meta-analysis were on 
296 mites count changes. Other parameters evaluating efficacy of treatments (e.g. tears quality 
297 [19,23], specific questionnaires [19,29,31,32,46], infrared thermography [23]) were limited to 
298 few studies and differing, precluding further analyses.
299
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300 Conclusion
301 Except usual lid hygiene for mites count, CHEO for both eradication rate and symptoms, and 
302 CHEO, 2% metronidazole ointment, and systemic metronidazole for symptoms, all treatments 
303 were efficient. TTO, T4O and pilocarpine gel are interesting molecules to elaborate new 
304 eyewashes as first-line local treatment of Demodex blepharitis. As second-line treatment or in 
305 severe cases, systemic treatment as ivermectin or metronidazole could be used in association 
306 with local treatments. 
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308 Abbreviations and Acronyms
309 CHEO= Children's Hospital of Eastern Ontario (cholestyramine 5% ointment); CONSORT= 
310 consolidated standards of reporting trials; ES= effect size; INR= International Normalized 
311 Ratio; OLSP= Ocusoft lid scrub plus; SIGN= Scottish Intercollegiate Guidelines Network; 
312 STROBE= strengthening the reporting of observational studies in epidemiology; TTFW= Dr 
313 Organic Tea Tree Face Wash; TTO= tea tree oil; T4O= terpinen-4-ol; US= United State of 
314 America; 95CI= 95% confidence interval.
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Appendix 1. Details on study characteristics, quality of articles (Figures 2 and 3), method of 
Demodex identification, type of treatments, protocol for each treatment, inclusion and 
exclusion criteria of each included study, population, aims and outcomes of included studies.
All articles were written in English except one in Spanish [14]. Included studies came from all 
continents: 6 from Asia [22,28–30,32,46], 3 from Europe [14,18,31], 2 from South 
America[19,21], 6 from North America [15,16,23–25,27], 1 from Oceania [26] and 1 from 
Africa [20].
Quality of articles
Quality assessment of the 19 included studies was performed by STROBE and SIGN Cohort 
Studies criteria concerning observational studies, CONSORT and SIGN Controlled Trials 
criteria concerning the randomized clinical trials. There were 14 observational studies 
[14,16,18,19,21–24,26–28,30,32,46] and 5 randomized clinical trials [15,20,25,29,31]. Results 
of STROBE criteria varying from 63.6 [14] to 84.8% [24], with a mean score of 75.1 ± 6.08. 
Results of CONSORT criteria varying from 72.9 [31] to 78.3% [20], with a mean score of 75.6 
± 2.70. Overall, the studies performed the best in methods and introduction sections and worst 
in the discussion section. Results of SIGN Cohort Studies criteria varying from 46.1 [24] to 
92.3% [16] for Yes responses, with a mean score of 63.2 ± 10.9. Results of SIGN Controlled 
Trials criteria varying from 55.5 [31] to 77.7% [20,25,29] for Yes responses, with a mean score 
of 71.1 ± 9.9 (Fig 2 and Fig 3).
Method of Demodex identification
All studies used conventional parasitological examination to prove Demodex infestation in the 
base of eyelash [14–16,18,18–32]. Eyelashes were sampled on all eyelids of both eyes for all 
included studies [14–16,18,18–32], with [22–25,27–29,32] or without [14–16,18–21,30,31,46] 
cylindrical dandruff. All studies using eyelashes with cylindrical dandruff sampled two 
eyelashes per eyelid [22–25,27–29,32]. For studies sampling eyelashes without cylindrical 
dandruff, the number of eyelashes sampled per eyelid was three [21,46], five [14], or six [19]. 
When the eyelashes were sampled, different conservations’ solutions were used like glycerine 
or oil [20,46], saline solution [14,23,25,27,28,32], 2% methylcelluloses [19] or a mix of 20 
microliters saline solution + 20 microliters 100% alcohol [22,24,29]. The examination unfolded 
by ×50 and ×100 magnification under light microscopy [14,16,18,20,23,25,27,32,46] or ×100 
and ×400 magnification [14,29] or slip lamp microscopy [22,24,26,28,30,31]. All studies have 
measured and evaluated infestation in naked eye except one [46].
Type of treatments
A total of 13 different treatments were used: 6 studies used 50% TTO [22–24,27–29], 4 used 
5% TTO in their treatment protocol [18,32,46], 3 used T4O eyewash [25,30,31], 2 used 4% 
pilocarpine gel [15,16], 6 used usual lid hygiene as principal treatment or control 
[15,16,25,27,29,31], 1 used Cilclar (1.5% boric acid) + 2% yellow mercury oxide ointment + 
ether application [14], 1 used 5% cholestyramine ointment called CHEO (because it was 
developed initially by the Children's Hospital of Eastern Ontario) [32], 1 used OcuSoft Lid 
Scrub Plus (OLSP)(1,2-octanediol) [31], 1 used Naviblef (0.02% TTO) [18], 1 used 2% 
metronidazole ointment [18], 4 used systemic ivermectin [18–21], 1 used systemic 
metronidazole lonely [20], and 1 used systemic metronidazole + ivermectin association [18]. 
In total, 4 studies used systemic treatments [18–21] and 16 studies used local treatments [14–
16,22–32,46], with one study using both systemic and local treatments [18].
Protocol for each treatment
50% TTO was used once a week during one month, in the hospital office, to scrub the lash roots 
for 3 sessions (10 minutes interval) with a drop of 0.5% proparacaine because of eyes irritation 
and burning sensation of 50% TTO. In addition, at home, TTO shampoo and eyelid hygiene 
massage were used twice daily during 1 month and then one daily thereafter [22–24,28,29].
5% TTO was used in two different packaging: in eyelid gel [46] or in eyelid oil [18,26,28,32]. 
Patients applied TTO at home on the eyelash, twice daily [18,32,46] or once after washing the 
face before sleeping [26], during 1 [18,32,46] or 3 months [26].
T4O, a major component of TTO, was used in two devices. Cliradex lid scrub device applied 
twice daily and Dr Organic Tea Tree Face Wash (TTFW) containing 38% of T4O and applied 
twice daily, both during 3 months [25,30,31].
4% pilocarpine gel was spread once in the evening on the base of eyelashes, and removed in 
the morning, for 2 weeks [15,16].
Usual lid hygiene consisted of scrubbing eyelashes with saline solution, warm massage and 
soap solution once or twice daily [15,16,25,27,29]. No other treatments were applied except in 
one study where BlephEx™ microblepharoexfoliation device was used at home to provide 
debridement and exfoliation at the lash margin [31].
Cilclar 1.9% (Novartis) and 2% oxide mercuric ointment were used twice and once daily at 
home, respectively, during 6 weeks, and ether was applied once a week in hospital office [14].
CHEO ointment, containing 0.5% cholestyramine in petroleum jelly, was spread by lid massage 
for 4 weeks [32].
OcuSoft Lid Scrub Plus (OLSP) contained 1,2-octanediol. This substance which has been 
shown to have pediculicide potential was scrubbed on the base of eyelashes in circular 
movements, once daily at home during 4 weeks [31]. 
Naviblef lid foam, containing 0.02% diluted TTO, was administered once in the morning to 
clean the lids, eye brow and face skin during 2 months [18].
2% metronidazole ointment was administered to the margins of the lower and upper lids once 
daily at bed time for 2 months [18].
Ivermectin was administered per os, 6 mg twice at a 14-day interval [18], 6 mg twice at a 14-
day interval [21], or 200 µg/kg at a 7-day interval [19,20].
Metronidazole was administered per os, 1 g per day during 10 days, [18] or 750 mg per days 
during two weeks in association with 200 µg/kg of ivermectin at a 7-day interval [20].
Inclusion and exclusion criteria
All studies included patients diagnosed with chronic and treatment-resistant blepharitis, and 
with a proven parasitological ocular demodicosis [14–16,18,18–32]. All studies included adults 
(>18 years old) [14–16,18–27,29–32,46], except one study without age criteria [28]. Most 
studies excluded the use of topical or systemic anti-inflammatory and antibacterial medications 
[16,19,20,23,25–27,29,31,32] and any kind of surgery prior to inclusion [19,20,25,29,31].
Population
Sample size: We included a total of 934 patients, ranging from 5 [18] to 233 [26], for a total 
of 1741 eyes treated for Demodex blepharitis, ranging from 10 [16,18] to 266 [26] in each 
included studies.
Gender: A total of 280 men and 521 women were included with a proportion of female ranging 
from 20 [20] to 80% [16]. Four studies did not specify gender [15,18,27,31].
Age: All studies included adults [14–16,18–27,29–32,46], except one which included children 
[28]. Within each study, mean age ranged from 7.5 ± 2.5 [28] to 76.8 ± 5.0 years [16]. Age of 
patients for each study is reported in supplemental files (Appendix 2 to 5).
Aims and outcomes of included studies
All included studies aimed to evaluate efficacy and safety of treatments for Demodex 
blepharitis, based on clinical outcomes [14–16,18,18–32]. All studies reported mites count 
before and after the different treatments, eradication rate (no mites after treatment), and 
improvement of symptoms, except four, six and six studies which did not report mites count 
[15,18,19,25,26,28]. eradication rate [16,19,25,26,28], and improvement of symptoms 
[16,20,25,27,29,30], respectively.




